Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients

Li Ma1, Lisha Qi2, Shuangjing Li3, Qiang Yin1, Jinmei Liu1, Jingyi Wang2, Chunhua She1, Peng Li1, Qun Liu1, Xiaoguang Wang1 & Wenliang Li1

1 Department of Neuro-Oncology and Neurosurgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
2 Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
3 Department of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, China

Keywords
Brain metastasis; breast cancer; HDAC inhibitor; histone deacetylases.

Abstract
Background: Brain metastasis is an unsolved clinical problem in breast cancer patients due to its poor prognosis and high fatality rate. Although accumulating evidence has shown that some pan-histone deacetylase (HDAC) inhibitors can relieve breast cancer brain metastasis, the specific HDAC protein involved in this process is unclear. Thus, identifying a specific HDAC protein closely correlated with breast cancer brain metastasis will not only improve our understanding of the functions of the HDAC family but will also help develop a novel target for precision cancer therapy.

Methods: Immunohistochemical staining of HDAC1, HDAC2, and HDAC3 in 161 samples from breast invasive ductal carcinoma patients, including 63 patients with brain metastasis, was performed using the standard streptavidin-peroxidase method. The relationships between HDAC1, HDAC2, and HDAC3 and overall survival/brain metastasis-free survival/post-brain metastatic survival were evaluated using Kaplan-Meier curves and Cox regression analyses.

Results: HDAC1, HDAC2, and cytoplasmic HDAC3 all displayed typical oncogenic characteristics and were independent prognostic factors for the overall survival of breast cancer patients. Only cytoplasmic HDAC3 was an independent prognostic factor for brain metastasis-free survival. Cytoplasmic expression of HDAC3 was further upregulated in the brain metastases compared with the matched primary tumors, while nuclear expression was downregulated. The HDAC1, HDAC2, and HDAC3 expression levels in the brain metastases were not correlated with survival post-brain metastasis.

Conclusions: Our studies first demonstrate a critical role for HDAC3 in the brain metastasis of breast cancer patients and it may serve as a promising therapeutic target for the vigorously developing field of precision medicine.

Key points
Significant findings of the study
Cytoplasmic HDAC3 is an independent prognostic factor for the overall survival and brain metastasis-free survival of breast cancer patients.
What this study adds
Cytoplasmic expression of HDAC3 was further upregulated in the brain metastases compared with the matched primary tumours, while nuclear expression was downregulated.
Introduction

An estimated 20% of cancer patients will develop brain metastases, with the majority of brain metastases originating from lung cancer (20%–56% of patients), breast cancer (5%–20%), or melanoma (7%–16%). The incidence of brain metastasis (BM) in breast cancer patients is increasing year by year partly due to the rapid progress in the multimodal treatments of breast cancer; however, once brain metastasis occurs, the prognosis of these patients will remain very poor, with the two-year survival rate in single digits. Although several genetic events, such as changes in ST6GALNAC5, CXCR4/CXCL12, and Slit2/Robo1, have been sporadically reported to correlate with breast cancer brain metastasis (BCBM) in the past few decades, the mechanisms underlying the central nervous system (CNS) relapse of breast cancer remain largely unknown.

Histone deacetylases (HDACs) play an important role in post-translational modification in mammalian cells by removing acetyl groups from various histone and nonhistone proteins. To date, 18 histone deacetylases have been identified and categorized into four different classes (class I, II, III and IV) based on their homology. In tumorigenesis, the finely tuned acetylation status at the whole proteome level might be disrupted by dysregulated HDACs, and HDAC inhibitors could enable the re-establishment of cellular acetylation-deacetylation homeostasis, thus reversing cancer initiation and progression. To date, numerous synthetic or natural inhibitors that target class I, II, and IV HDACs have been developed, most of which are pan inhibitors for two or more HDAC classes. Accumulating evidence suggests that HDAC inhibitors can effectively relieve brain metastases from breast cancer. Palmieri et al. reported that the HDAC inhibitor vorinostat prevented the development of 231-BR (a brain trophic subline of MDA-MB-231 human breast cancer cell line) micrometastases by 28% and large metastases by 62% compared with those in vehicle-treated mice; Kim et al. observed that the HDAC inhibitor SB939 reduced 4T1-Br4 (a brain trophic subline of 4T1 mouse breast cancer cell line) metastasis to the brain in vivo and had potent radio-sensitizing properties in vitro.

Although increasing evidence has shown that pan-HDAC inhibitors such as vorinostat and SB939 can reduce the occurrence of BCBM, it is still unclear which specific HDAC protein plays a key role in the process of breast cancer cell metastasis to the brain and whether such effect is directly caused by a particular HDAC protein or derived from HDAC downstream gene targets. In this study, we used a cohort of 161 patients with invasive ductal carcinoma (IDC) of the breast to investigate the specific roles of different HDAC proteins in BCBM. The related results will not only improve our understanding of the functions of the HDAC family but will also help develop more specific and efficient antitumour strategies based on a single therapeutic target. Since HDAC1, HDAC2, and HDAC3 are the most common histone deacetylases in human tissues with a relatively high abundance and have already been reported elsewhere to be potential oncogenes in breast cancer, our studies mainly focus on these three HDAC proteins.

Methods

Breast Cancer patient selection and clinical information

A total of 63 IDC patients with brain metastasis, diagnosed between 2003 and 2018, were selected from the archives of the Pathology Department and Breast Pathology Department of Tianjin Medical University Cancer Institute and Hospital (TMUCIH). Paraffin-embedded tissue chips of 98 patients with IDC but without brain metastasis were purchased from Shanghai Outdo Biotech Company (HBreD139Su01). A total of 139 primary breast tumors and 45 brain metastases were collected for HDAC immunohistochemical staining in our study. Among them, 24 were matched samples of primary and brain metastatic tumors from the same person. This study was reviewed and approved by the Ethics Committee of TMUCIH. The median age of the 161 patients with IDC was 51 years (range, 26–82), and they were all female. None had received neoadjuvant chemotherapy or preoperative radiotherapy. The patients were followed-up for 2–158 months, and 79 (49.1%) patients died of tumors. Detailed information on the clinicopathological characteristics of the 161 patients can be found in Table S1.

Immunohistochemical staining

Immunohistochemical staining of HDAC1, HDAC2, and HDAC3 was performed with the streptavidin-peroxidase (S-P) method as previously reported. Antigen retrieval was performed at 121°C for 2 minutes 30 seconds using citrate buffer (pH 6.0). After serial blocking with hydrogen peroxide and normal horse serum, the tissue chips and sections were incubated with primary monoclonal antibody against HDAC1 (cat. no. 10197-1-AP, Proteintech), HDAC2 (cat. no. 12922-3-AP, Proteintech) or HDAC3 (cat. no. 10255-1-AP, Proteintech) at 4°C overnight.

Evaluation of staining

The tissue chips and sections stained immunohistochemically for HDAC1, HDAC2, and HDAC3 were reviewed and scored separately by two
Figure 1 HDAC1, HDAC2, and HDAC3 were upregulated in breast cancer tissues and correlated with worse prognosis in breast cancer patients. (a) Representative immunohistochemical (IHC) staining photos of HDAC1, HDAC2, and HDAC3 in breast specimens. HDAC1, HDAC2, and HDAC3 levels were obviously elevated in the tumor tissues compared to the non-neoplastic adjacent tissues of patients with invasive ductal carcinoma (IDC). Yellow boxes indicated mammary ducts. Scale bars, 100 μm. (b) Representative IHC photos of three different kinds of HDAC3 subcellular localization. Scale bars, 100 μm. (c–f) Overall survival (OS) curves of 139 IDC patients with different HDAC1 (g–h) HDAC1 Low (i–j) HDAC1 High
HDAC3 predicts brain metastasis

L. Ma et al.

Statistical analysis

Overall survival (OS) was measured from the date of the breast cancer diagnosis to the date of death or the last follow-up; brain metastasis-free survival was defined as the time from the date of the breast cancer diagnosis to the date of the brain metastasis diagnosis; survival after brain metastasis was measured from the date of the brain metastasis diagnosis to the date of death or the last follow-up. Survival outcomes were evaluated using the Kaplan-Meier method, and differences between groups were compared by using log-rank statistics. Quantitative data of HDAC1, HDAC2, and HDAC3 staining are expressed as the mean ± standard deviation (SD). Paired t-tests were used to evaluate the statistical significance between matched samples of primary tumors and brain metastases, and unpaired t-tests with Welch’s correction were used to evaluate the differences of HDAC expression in patients with and without brain metastasis. The χ² test was used to study the correlation between molecular subtypes and HDAC expression. Nonparametric Spearman’s correlation analysis was used to assess the association between two variables. Univariate and multivariate Cox proportional hazards models were used to determine the associations of the clinical-pathological parameters with survival outcomes. A variable with \( P < 0.10 \) in the univariate analysis was considered eligible for later multivariate analysis.

All reported \( P \)-values were two-sided, and differences reaching \( P < 0.05 \) were considered statistically significant. Statistical analyses were performed with IBM SPSS Statistics 19 and GraphPad Prism 7.

Results

HDAC1, HDAC2, and HDAC3 were upregulated in breast cancer tissues and correlated with worse prognosis in breast cancer patients

To identify whether histone deacetylases have direct relationships with the prognosis of breast cancer patients, we assessed the HDAC1, HDAC2, and HDAC3 protein expression data from a combined cohort of 161 breast cancer cases. Our results showed that the expression of HDAC1/HDAC2/HDAC3 increased significantly in the tumor tissues compared to the adjacent non-neoplastic breast tissue (Fig 1a), indicating that the three histone deacetylases play vital roles in the initiation and development of breast cancer. Notably, HDAC1 and HDAC2 were predominantly located in the nucleus of breast cancer cells. However, the subcellular localization of HDAC3 varied in tumor cells and could be in the nucleus, cytoplasm, or both (Fig 1b). Therefore, the nuclear expression of HDAC1 and HDAC2 was scored and analyzed in the following study, while the nuclear and cytoplasmic expression of HDAC3 was studied separately in our study to ensure the accuracy and completeness of the results. The correlation between HDAC1, HDAC2, and HDAC3 expression and overall survival was investigated with Kaplan-Meier survival analysis. As expected, the patients with higher HDAC1, HDAC2,
Table 1 HDACs expression exhibited different roles in overall survival of IDC patients (n = 16)

| Clinicopathological characteristics | Univariate | Multivariate | Multivariate | Multivariate | Multivariate | Multivariate |
|------------------------------------|------------|--------------|--------------|--------------|--------------|--------------|
|                                    | HR (95%CI) | P-value      | HR (95%CI)   | P-value      | HR (95%CI)   | P-value      |
| Age, years                         |            |              |              |              |              |              |
| <48                                | 1          |              |              |              |              |              |
| ≥48                                | 1.398      | 0.144        |              |              |              |              |
|                                    | (0.892-2.192) |       |              |              |              |              |
| Tumor size, cm                    |            |              |              |              |              |              |
| ≤2                                 | 1          |              | 1            |              | 1            |              |
|                                    | 3.432      | 0.009        | 4.918        | 0.030        | 3.942        | 0.061        |
|                                    | (1.363-8.640) |       | (1.165-20.752) |              | (0.937-16.581) |              |
|                                    | 10.957     | 0.000        | 13.005       | 0.001        | 9.130        | 0.005        |
|                                    | (4.141-28.993) |       | (2.753-61.445) |              | (1.966-42.403) |              |
|                                    | 1          |              |              |              | 1            |              |
|                                    | 4.190      |              | 4.918        |              | 9.614        |              |
|                                    | (1.000-17.565) |       | (2.077-44.510) |              | (2.177-45.912) |              |
|                                    | 1          |              |              |              | 1            |              |
|                                    | 4.105      |              | 13.005       |              | 9.998        |              |
|                                    | (0.981-17.188) |       | (2.753-61.445) |              | (2.177-45.912) |              |
| Histological grade                |            |              |              |              |              |              |
| I                                  | 1          |              | 1            |              | 1            |              |
|                                    | 7.343      | 0.049        | 3.966        | 0.184        | 3.283        | 0.250        |
|                                    | (1.011-53.346) |       | (0.518-30.345) |              | (0.433-24.921) |              |
|                                    | 32.775     | 0.001        | 13.491       | 0.014        | 10.961       | 0.024        |
|                                    | (4.422-242.943) |       | (1.686-107.931) |              | (1.377-87.253) |              |
|                                    | 1          |              |              |              | 1            |              |
|                                    | 3.757      |              | 3.578        |              | 3.076        |              |
|                                    | (0.403-23.476) |       | (0.472-27.109) |              | (2.077-44.510) |              |
| Lymph node status                 |            |              |              |              |              |              |
| Negative                           | 1          |              | 1            |              | 1            |              |
|                                    | 1.952      | 0.009        | 2.092        | 0.014        | 1.781        | 0.056        |
|                                    | (1.182-3.223) |       | (1.163-3.764) |              | (0.985-3.218) |              |
| Positive                           | 1          |              | 1            |              | 1            |              |
|                                    | 0.303      | 0.000        | 0.875        | 0.685        | 0.803        | 0.491        |
|                                    | (0.190-0.483) |       | (0.459-1.669) |              | (0.431-1.498) |              |
| ER status                          |            |              |              |              |              |              |
| Negative                           | 1          |              | 1            |              | 1            |              |
|                                    | 0.303      | 0.000        | 0.875        | 0.685        | 0.803        | 0.491        |
|                                    | (0.190-0.483) |       | (0.459-1.669) |              | (0.431-1.498) |              |
| Positive                           | 1          |              | 1            |              | 1            |              |
|                                    | 0.341      |              | 0.515        | 0.046        | 0.489        | 0.023        |
|                                    | (0.211-0.550) |       | (0.269-0.989) |              | (0.264-0.906) |              |
| PR status                          |            |              |              |              |              |              |
| Negative                           | 1          |              | 1            |              | 1            |              |
|                                    | 0.303      | 0.000        | 0.875        | 0.685        | 0.803        | 0.491        |
|                                    | (0.190-0.483) |       | (0.459-1.669) |              | (0.431-1.498) |              |
| Positive                           | 1          |              | 1            |              | 1            |              |
|                                    | 0.341      |              | 0.515        | 0.046        | 0.489        | 0.023        |
|                                    | (0.211-0.550) |       | (0.269-0.989) |              | (0.264-0.906) |              |
| HER2 status                        |            |              |              |              |              |              |
| Negative                           | 1          |              |              |              |              |              |
|                                    | 1.465      | 0.107        |              |              |              |              |
|                                    | (0.921-2.332) |       |              |              |              |              |
| Positive                           | 1          |              |              |              |              |              |
|                                    | 1.874      | 0.019        | 1.823        | 0.030        |              |              |
|                                    | (1.111-3.162) |       | (1.059-3.136) |              |              |              |
nuclear HDAC3 and cytoplasmic HDAC3 usually had a worse prognosis (Fig 1c–f, all P < 0.05). To better match the evaluation criteria of HDAC3 in the bc-GenExMiner database, which contained 4903 breast cancer patients (that database did not state whether HDAC3 was nuclear or cytoplasmic), we classified the cases with high nuclear or cytoplasmic expression of HDAC3 into the C-high/N-high group, and other cases were classified into the Others group. Accordingly, another survival curve of patients with different HDAC3 levels was produced as Fig 1g, and once again, patients with higher HDAC3 expression exhibited shorter overall survival (P < 0.05). We next investigated the relationship between HDAC expression and patient prognosis in the bc-GenExMiner database. The trends in the above database were consistent with our previous conclusions; that is, higher HDAC1/HDAC2/HDAC3 expression often indicates a worse prognosis (Fig 1h–j, all P < 0.05). Thus, HDAC1, HDAC2, and HDAC3 all displayed typical oncogenic characteristics and were important in the early development of breast cancer and later survival of patients.

We also analyzed the roles of other common clinicopathological characteristics in the prognosis of those IDC patients in addition to HDAC1, HDAC2, and HDAC3. The univariate results of Cox regression analysis showed that increased tumor size/histological grade/lymph node invasion/HDAC1/HDAC2/nuclear HDAC3/cytoplasmic HDAC3 were significantly associated with shorter overall survival, while positive ER or PR was associated with prolonged overall survival (Table 1). In multivariate Cox regression analysis, HDAC1, HDAC2, or cytoplasmic HDAC3 was still an independent prognostic factor for the overall survival of breast cancer patients after correction for tumor size, histological grade, lymph node status, ER and PR (Table 1). Additionally, nuclear HDAC3 was not an independent prognostic factor in the multivariate analysis, suggesting that the influence of nuclear HDAC3 on the overall survival of such patients might be affected by some other variables.

### Patients with higher expression of HDAC3 exhibited earlier occurrence of brain metastasis (BM), and patients with BM had higher expression of HDAC3 than those without BM

The associations between HDAC1/HDAC2/HDAC3 and classical clinicopathological characteristics such as age, tumor size, histological grade, lymph node status, ER, PR, HER2, brain metastasis and molecular subtypes were analyzed by Spearman’s rank-correlation test and χ² test. As shown in Table 2, only cytoplasmic HDAC3 exhibited a significant correlation with histological grade, lymph node...
Table 2 Relationship between clinicopathological characteristics and HDACs expression in IDC patients (n = 139)

| Clinicopathological characteristics | HDAC3 (cytoplasm), n | HDAC3 (nucleus), n | HDAC1, n | HDAC2, n |
|-------------------------------------|----------------------|---------------------|---------|---------|
| Age, years                          |                      |                     |         |         |
| <48                                 | 57 42 15             | 45 12              | 38 19   | 49 8    |
| ≥48                                 | 82 62 20             | 58 24              | 59 23   | 55 27   |
| Tumor size, cm                      |                      |                     |         |         |
| ≤2                                  | 21 18 3              | 16 5               | 14 7    | 16 5    |
| 2-5                                 | 91 68 23             | 71 20              | 65 26   | 70 21   |
| >5                                  | 25 16 9              | 14 11              | 16 9    | 16 9    |
| Histological grade                  |                      |                     |         |         |
| I                                   | 13 12 1              | 9 4                | 10 3    | 10 3    |
| II                                  | 97 74 23             | 75 22              | 68 29   | 74 23   |
| III                                 | 27 16 11             | 17 10              | 17 10   | 18 9    |
| Lymph node status                   |                      |                     |         |         |
| Negative                            | 52 44 8              | 43 9               | 36 16   | 39 13   |
| Positive                            | 86 59 27             | 59 27              | 60 26   | 64 22   |
| ER status                           |                      |                     |         |         |
| Negative                            | 44 28 16             | 28 16              | 29 15   | 34 10   |
| Positive                            | 94 76 18             | 75 19              | 68 26   | 70 24   |
| PR status                           |                      |                     |         |         |
| Negative                            | 62 44 18             | 15 17              | 40 22   | 46 16   |
| Positive                            | 76 60 16             | 58 18              | 57 19   | 58 18   |
| HER2 status                         |                      |                     |         |         |
| Negative                            | 90 70 20             | 69 21              | 62 28   | 71 19   |
| Positive                            | 48 34 14             | 34 14              | 35 13   | 33 15   |
| Brain metastasis                    |                      |                     |         |         |
| No                                  | 98 81 17             | 77 21              | 69 29   | 75 23   |
| Yes                                 | 41 23 18             | 26 15              | 28 13   | 29 12   |
| Molecular subtypes                  |                      |                     |         |         |
| Luminal                             | 98 80 18             | 78 20              | 72 26   | 72 26   |
| HER2 overexpression                 | 14 7 7               | 8 6                | 8 6     | 11 3    |
| Triple negative                     | 26 17 9              | 17 9               | 17 9    | 21 5    |

Some data were missing.

$r_s$ or $\chi^2$: Spearman’s rank correlation test for age, tumor size, histological grade, lymph node status, ER, PR, HER2, and brain metastasis; $\chi^2$ for molecular subtypes.

$P$-value was calculated by Spearman’s rank correlation test for age, tumor size, histological grade, lymph node status, ER, PR, HER2, and brain metastasis; $P$-value was calculated by $\chi^2$ test for molecular subtypes.

$^{*}$Indicates statistical significance ($P < 0.05$).

$^{†}$HDAC3 (cytoplasm): Luminal vs. HER2 overexpression: $P = 0.021$, $\chi^2 = 5.363$; Luminal versus Triple negative: $P = 0.074$, $\chi^2 = 3.185$; HER2 overexpression versus Triple negative: $P = 0.343$, $\chi^2 = 0.897$.

$^{†}$HDAC3 (cytoplasm): Luminal vs. HER2 overexpression: $P = 0.021$, $\chi^2 = 5.363$; Luminal versus Triple negative: $P = 0.074$, $\chi^2 = 3.185$; HER2 overexpression versus Triple negative: $P = 0.343$, $\chi^2 = 0.897$.
HDAC3 predicts brain metastasis

Figure 2 Patients with higher expression of HDAC3 exhibited earlier occurrence of brain metastasis (BM), and patients with BM have higher expression of HDAC3 than those without BM. (a-b) Brain metastasis-free survival (BMF) curves of 139 IDC patients with different cytoplasmic HDAC3 (a) C-low (——) HDAC3 C-high (—) HDAC3 C-low-censored (→) HDAC3 C-high-censored, and nuclear HDAC3 (b) levels (——) HDAC3 N-low (——) HDAC3 N-high-censored (→) HDAC3 N-high-censored. P-values of the Kaplan-Meier plots in (a-b) were calculated by log-rank tests in SPSS. (c-d) Cytoplasmic HDAC3 (c); and nuclear HDAC3 (d) IHC scores of IDC patients with BM (n = 41) and without BM (n = 98) were compared quantitatively and are shown as the mean ± SD visually. P-values of (c-d) were calculated by unpaired t-test with Welch’s correction. *P < 0.05.

Table 3 HDACs expression exhibited different roles in the onset of brain metastasis of IDC patients (n = 161)

| Clinicopathological characteristics | Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value |
|-----------------------------------|------------------------|---------|--------------------------|---------|--------------------------|---------|
| Age, years                        |                        |         |                          |         |                          |         |
| <48                               | 1                      |         |                          |         |                          |         |
| ≥48                               | 1                      | 0.760(0.463-1.250) | 0.280 | /                        | /       | /                        | /       |
| Tumor size†, cm                   |                        |         |                          |         |                          |         |
| ≤2                                | 1                      |         |                          |         |                          |         |
| 2-5                               | 1                      | 1.409(0.647-3.070) | 0.388 | 2.576(0.599-11.086) | 0.204  | 2.550(0.597-10.900) | 0.207  |
| >5                                | 1                      | 5.159(2.220-11.986) | 0.000* | 7.317(1.569-34.120) | 0.011* | 8.975(1.953-41.239) | 0.005* |
| Lymph node status*                |                        |         |                          |         |                          |         |
| Negative                          | 1                      |         |                          |         |                          |         |
| Positive                          | 1                      | 1.466(0.858-2.504) | 0.161 | /                        | /       | /                        | /       |
| ER status†                        |                        |         |                          |         |                          |         |
| Negative                          | 1                      |         |                          |         |                          |         |
| Positive                          | 1                      | 0.279(0.165-0.471) | 0.000* | 0.499(0.216-1.153) | 0.104  | 0.541(0.231-1.266) | 0.157  |
| PR status†                        |                        |         |                          |         |                          |         |
| Negative                          | 1                      | 0.360(0.211-0.614) | 0.000* | 0.448(0.190-1.054) | 0.066  | 0.417(0.164-1.058) | 0.066  |
| HER2 status†                      |                        |         |                          |         |                          |         |
| Negative                          | 1                      | 1.655(0.984-2.783) | 0.057 | 1.264(0.642-2.487) | 0.497  | 1.045(0.521-2.093) | 0.902  |
| Positive                          | 1                      |         |                          |         |                          |         |
| HDAC1 status†                     | Low                    |         |                          |         |                          |         |
|                                   | High                   | 1.370(0.705-2.661) | 0.353 | /                        | /       | /                        | /       |
| HDAC2 status†                     | Low                    |         |                          |         |                          |         |
|                                   | High                   | 1.555(0.793-3.051) | 0.199 | /                        | /       | /                        | /       |
| HDAC3 status† (nucleus)           | Low                    |         |                          |         |                          |         |
|                                   | High                   | 2.305(1.219-4.360) | 0.010* | 1.712(0.843-3.477) | 0.137  | 3.386(1.724-6.650) | 0.000* |
| HDAC3 status† (cytoplasm)         | Low                    |         |                          |         |                          |         |
|                                   | High                   | 3.932(2.112-7.322) | 0.000* | /                        | /       | /                        | /       |

Some data were missing.

*Indicates statistical significance (P < 0.05).

P-value was calculated by Cox regression analysis.
status, ER, molecular subtypes, and especially brain metastasis ($P < 0.05$).

Kaplan-Meier plots of brain metastasis-free survival (BMF) in the same population further demonstrated that brain metastasis occurred earlier in those patients with high expression levels of HDAC3 (available for both subcellular locations, Fig 2a,b, all $P < 0.05$), while HDAC1 and HDAC2 again were not associated with brain metastases (Fig S1a and S1b).

Unsurprisingly, cytoplasmic HDAC3 in the patients with brain metastasis was much higher than that in the patients without brain metastasis (Fig 2c, with vs. without: $33.900 \pm 8.373$ vs. $11.020 \pm 3.403$, $P = 0.014$); nuclear HDAC3 was also higher in the patients with brain metastasis than in those without brain metastasis (Fig 2d, with vs. without: $18.170 \pm 4.049$ vs. $9.235 \pm 1.771$, $P = 0.048$); there was no significant difference in the average score or distribution of HDAC1/HDAC2 between these two groups of patients (Fig S1c and S1d).

The univariate results of Cox regression analysis showed that increased tumor size/nuclear HDAC3/cytoplasmic HDAC3 were significantly associated with earlier occurrence of brain metastasis, while positive ER or PR was associated with delayed brain metastasis (Table 3). In multivariate Cox regression analysis, cytoplasmic HDAC3 was still an independent prognostic factor for the occurrence of brain metastasis in the breast cancer patients after correction for tumor size, ER, PR, and HER2 (Table 3); nuclear HDAC3 was not an independent prognostic factor in the multivariate analysis, which suggested that the influence of nuclear HDAC3 on brain metastasis in such patients was also possibly linked with other variables.

### Cytoplasmic expression of HDAC3 upregulated in brain metastasis specimens compared with matched primary tumor specimens and nuclear HDAC3 expression was inversely downregulated

Representative immunohistochemical staining images of HDAC3 in the primary breast tumors and their matched brain metastases are shown in Fig 3a. The results visually demonstrated that the concentrated area of positive HDAC3 staining changed from the nucleus in the primary tumors to the cytoplasm in the matched brain metastases in these two cases. The changes in cytoplasmic and nuclear HDAC3 scores of the matched samples are shown in Fig 3b,c on a case-by-case basis (note: scores and lines overlapped in some cases). **$P < 0.01$.**

![Figure 3](image-url)
higher metastatic potential, and therefore, such cells were enriched in the brain metastases.

There were no significant differences in HDAC1 and HDAC2 expression between the primary tumors and their matched brain metastases (Fig S2a,b).

**HDAC1, HDAC2, and HDAC3 expression levels in brain metastases were not correlated with survival after brain metastasis in IDC patients**

We next explored whether HDACs in brain metastases were correlated with prognosis after brain metastasis. Kaplan-Meier survival analysis showed that the HDAC1, HDAC2, and HDAC3 expression levels all had no significant effect on the post-brain metastatic survival of 45 IDC patients (Fig S3a,b, Fig 4a,b, all $P > 0.05$).

The univariate results of Cox regression analysis showed that receiving CNS surgery or radiotherapy could prolong the post-brain metastatic survival of these patients, while the occurrence of meningeal metastasis complication shortened their post-brain metastatic survival (Table 4); HDAC1, HDAC2, and HDAC3 expression levels and other clinical characteristics, such as age, number of brain metastases and extracranial metastases, were not correlated with the prognosis after brain metastasis, and they were not included in the multivariate analysis (Table 4, all $P > 0.1$).

In multivariate Cox regression analysis, CNS radiotherapy and survival after brain metastasis of IDC patients were shown in the corresponding Kaplan-Meier plots CNS surgery (d, n=63). P-values were calculated by log-rank tests in SPSS.

**Figure 4** Survival after brain metastasis of IDC patients was not correlated with HDAC3 expression in brain metastases; however, no meningeal metastasis complication, CNS surgery, or CNS radiotherapy was associated with a better patient prognosis. (a–e) The relationship between cytoplasmic HDAC3 (a, expression of brain metastases, $n=45$) (HDAC3 C-low (---) HDAC3 C-high (----) HDAC3 C-low-censored (— —) HDAC3 C-high-censored (— —)) with meningeal metastasis complication (c, $n=59$) (without meningeal metastasis (—) with meningeal metastasis (- -)) with CNS surgery (d, $n=63$), or CNS radiotherapy (e, $n=59$) (without CNS radiotherapy (—) with CNS radiotherapy (—)) with CNS radiotherapy-censored (— —) with CNS radiotherapy-censored and survival after brain metastasis of IDC patients were shown in the corresponding Kaplan-Meier plots CNS surgery (d, n=63). P-values were calculated by log-rank tests in SPSS.
and meningeal metastasis complication were still independent prognostic factors for the post-brain metastatic survival of these IDC patients (Table 4). The Kaplan-Meier plots more intuitively demonstrated the effects of meningeal metastasis complication, CNS surgery and radiotherapy on the post-brain metastatic survival (Fig 4c–e, all P < 0.01, median survival time: with meningeal metastasis versus without meningeal metastasis = 8 months versus 25 months; with CNS surgery versus without CNS surgery = 24 months versus 12 months; with CNS radiotherapy versus without CNS radiotherapy = 24 months versus 12 months).

**Discussion**

To date, the mechanisms responsible for the brain colonization of breast cancer cells remain poorly understood and little investigated, partly due to its relatively low incidence and the complexity of the blood-brain barrier (BBB).

Inspired by the positive results of pan-HDAC inhibitors in the research field of BCBM, we used a cohort of 161 patients with IDC to investigate the specific roles of different HDAC proteins in the process of BCBM. We found that although HDAC1, HDAC2, and HDAC3 all displayed typical oncogenic characteristics in the tumorigenesis and development of breast cancer, only patients with high expression of HDAC3 exhibited earlier occurrence of brain metastasis (BM), and the patients with BM had relatively higher HDAC3 expression than those without BM. Moreover, cytoplasmic expression of HDAC3 was upregulated, while nuclear HDAC3 expression was inversely downregulated in brain metastatic tumors. These results indicate that HDAC3 probably participates in not only the early phase, but also the middle and late stages of BCBM.

### Table 4: The roles of HDACs expression and other clinicopathological characteristics played in the prognosis of breast cancer patients after brain metastasis (n = 63)

| Clinicopathological characteristics | Univariate HR (95%CI) | P-value | Multivariate HR (95%CI) | P-value |
|------------------------------------|------------------------|---------|-------------------------|---------|
| **Age, years**                     |                        |         |                         |         |
| <48                                | 1                      |         |                         |         |
| ≥48                                | 1.278 (0.708-2.305)     | 0.416   |                         |         |
| **Number of brain metastases**     |                        |         |                         |         |
| Single                             | 1                      |         |                         |         |
| Multiple                           | 1.423 (0.726-2.792)     | 0.305   |                         |         |
| **Extracranial metastases** (lung, liver, bone) | | | | |
| No                                 | 1                      |         |                         |         |
| Yes                                | 1.211 (0.654-2.239)     | 0.543   |                         |         |
| **Meningeal metastasis complication** |                      |         |                         |         |
| No                                 | 1                      |         |                         |         |
| Yes                                | 5.944 (2.984-11.843)    | 0.000* | 4.568 (2.107-9.907)     | 0.000* |
| **CNS surgery**                    |                        |         |                         |         |
| No                                 | 1                      |         |                         |         |
| Yes                                | 0.405 (0.212-0.772)     | 0.006* | 0.714 (0.343-1.484)     | 0.367   |
| **CNS radiotherapy**               |                        |         |                         |         |
| No                                 | 1                      |         |                         |         |
| Yes                                | 0.293 (0.150-0.575)     | 0.000* | 0.346 (0.174-0.690)     | 0.003* |
| **HDAC1 status of brain metastases** |                      |         |                         |         |
| Low                                | 1                      |         |                         |         |
| High                               | 1.496 (0.689-3.250)     | 0.309   |                         |         |
| **HDAC2 status of brain metastases** |                      |         |                         |         |
| Low                                | 1                      |         |                         |         |
| High                               | 1.125 (0.0492-2.571)    | 0.780   |                         |         |
| **HDAC3 status (nucleus) of brain metastases** | | | | |
| Low                                | 1                      |         |                         |         |
| High                               | 1.224 (0.286-5.236)     | 0.785   |                         |         |
| **HDAC3 status (cytoplasm) of brain metastases** | | | | |
| Low                                | 1                      |         |                         |         |
| High                               | 1.509 (0.719-3.166)     | 0.277   |                         |         |

*Some data were missing.

*Indicates statistical significance (P < 0.05).
P-value was calculated by Cox analysis.
HDAC3 possesses a unique property among the class I family of HDACs, as it is able to shuttle between the nucleus and the cytoplasm, whereas the other family members (HDAC1, HDAC2, and HDAC8) are found primarily in the nucleus.\(^2,23\) HDAC3 contains one nuclear localization signal (NLS) and two different nuclear export sequences (NES).\(^2,24\) The biological function of HDAC3 varies with protein localization and cell type. For example, Park \textit{et al.} reported that the nuclear localization of HDAC3 was essential for the expression regulation of MDRI in drug-resistant cancer cell lines,\(^25\) and Escaffit \textit{et al.} demonstrated a crucial role of cytoplasmic HDAC3 in the apoptosis progression in Jurkat and U2OS cells.\(^23\) Herein, our studies first reveal that HDAC3 is closely related to the occurrence and development of brain metastasis in breast cancer patients, and moreover, the cytoplasmic expression of HDAC3 may play a more important role than nuclear expression in the metastatic process.

However, in our study, the HDAC3 expression level in the brain metastases was not correlated with post-brain metastatic survival. One plausible explanation is that survival after brain metastasis is influenced by many factors,\(^26\) such as the anatomical location of the brain metastasis, control of extracranial metastases, and the myriad of treatment options available; thus, the role of HDAC3 on post-brain metastatic survival is very likely to be overridden. Another possible reason is that the sample size of our study is still relatively small; if more breast cancer patients with brain metastasis are included, the effect of cytoplasmic HDAC3 on post-brain metastatic survival may become statistically significant.

Finally, we did not discuss the relationship between HDACs and extracranial metastasis of breast cancer in this article due to lack of complete metastasis information of patients in the tissue chips. Breast cancer has a greater chance of metastasizing to the lung and bone than to the brain,\(^4,21\) and among the IDC patients with brain metastasis in our study, 49.2\% (29/59) had at least one extracranial metastasis (unpublished data). Zhou \textit{et al.} reported that HDAC inhibitors such as psammaplins and trichostatin A could disrupt the organ-tropic (lung, bone, and brain) metastasis of MDA-MB-231 sublines.\(^27\) Thus, whether HDAC3 is specifically associated with brain metastasis, or is associated with multiple organ metastases in breast cancer patients requires further study.

**Acknowledgments**

The paraffin-embedded tissue slices of breast cancer patients with brain metastasis were kindly provided by Dr Yongjie Ma and Dr Feng Gu of Tianjin Medical University Cancer Institute and Hospital. We also thank Dr Yuanfu Xu of Chinese Academy of Medical Sciences & Peking Union Medical College for discussion. This work was supported by National Natural Science Foundation of China (81702481) and Natural Science Foundation of Tianjin (15JCQNJC44800 and 18JCYBJC27600).

**Disclosure**

The authors declare that there are no potential conflicts of interest.

**References**

1. Achrol AS, Rennert RC, Anders C \textit{et al.} Brain metastases. \textit{Nat Rev Dis Primers} 2019; 5: 5.
2. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. \textit{Carr Oncol Rep} 2012; 14: 48–54.
3. Berghoff AS, Schur S, Furerer LM \textit{et al.} Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. \textit{ESMO Open} 2016; 1: e000024.
4. Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H. Breast cancer brain metastases: Biology and new clinical perspectives. \textit{Breast Cancer Res} 2016; 18: 8.
5. Mills MN, Figura NB, Arrington JA \textit{et al.} Management of brain metastases in breast cancer: A review of current practices and emerging treatments. \textit{Breast Cancer Res Treat} 2020; 180: 279–300.
6. Chang G, Wang J, Zhang H \textit{et al.} CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells metastasis via the regulation of ERK1/2. \textit{Br J Cancer} 2014; 110: 916–27.
7. Bos PD, Zhang XH, Nadal C \textit{et al.} Genes that mediate breast cancer metastasis to the brain. \textit{Nature} 2009; 459: 1005–9.
8. Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. \textit{Clin Exp Metastasis} 2010; 27: 97–105.
9. Qin F, Zhang H, Ma L \textit{et al.} Low expression of Slit2 and Robo1 is associated with poor prognosis and brain-specific metastasis of breast cancer patients. \textit{Sci Rep} 2015; 5: 14430.
10. Li Y, Seto E, HDACs and HDAC inhibitors in cancer development and therapy. \textit{Cold Spring Harb Perspect Med} 2016; 6 (10): a026831.
11. Ediriweera MK, Tennekoon KH, Samarakoon SR. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. \textit{Drug Discov Today} 2019; 24: 685–702.
12. Garmpis N, Damaskos C, Garmpi A \textit{et al.} Histone deacetylases as new therapeutic targets in triple-negative breast cancer: Progress and promises. \textit{Cancer Genomics Proteomics} 2017; 14: 299–313.
13. Damaskos C, Garmpis N, Valsami S \textit{et al.} Histone deacetylase inhibitors: An attractive therapeutic strategy against breast cancer. \textit{Anticancer Res} 2017; 37: 35–46.
24 Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. Functional domains of histone deacetylase-3. J Biol Chem 2002; 277: 9447–54.

25 Park H, Kim Y, Park D, Jeoung D. Nuclear localization signal domain of HDAC3 is necessary and sufficient for the expression regulation of MDR1. BMB Rep 2014; 47: 342–7.

26 McArthur H. Breast cancer brain metastasis: An ongoing clinical challenge and opportunity for innovation. Oncology (Williston Park) 2016; 30: 934–5.

27 Zhou YD, Li J, Du L et al. Biochemical and anti-triple negative metastatic breast tumor cell properties of Psammaplins. Mar Drugs 2018; 16 (11): 442.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Table S1 The clinicopathological characteristics of 161 IDC patients.

Figure S1 HDAC1 & HDAC2 exhibited no statistically significant correlation with brain metastasis of IDC patients. (a–b) Brain metastasis-free survival (BMF) curves of 139 IDC patients with different HDAC1 (a) and HDAC2 (b) levels. P-value of the Kaplan-Meier plots in (a–b) were calculated by log-rank test in SPSS. (c–d) HDAC1 (c) and HDAC2 (d) IHC scores of IDC patients with BM (n = 41) and without BM (n = 98) were compared quantitatively and shown by mean ± SD visually. P-value of (c–d) were calculated by unpaired t-test with Welch’s correction, both P > 0.05. Figure S2 There were no significant differences of HDAC1 & HDAC2 expression between primary tumors and brain metastases of IDC patients. (a–b) HDAC1 (a) and HDAC2 (b) IHC scores of 24 primary breast tumors and matched brain metastases were shown by symbols and lines plot, and P-values were calculated by paired t-test (scores were overlapped in some cases, both P > 0.05). Figure S3 HDAC1 or HDAC2 expression in brain metastases was not correlated with the survival after brain metastasis of IDC patients. (a–b) The relationship between HDAC1 (a, expression of brain metastases, n = 45), HDAC2 (b, expression of brain metastases, n = 45) and survival after brain metastasis of IDC patients were shown in corresponding Kaplan-Meier plots, and P-value were calculated by log-rank test in SPSS.